Beyond Air, Inc. (XAIR) — SEC Filings
Beyond Air, Inc. (XAIR) — 50 SEC filings. Latest: 8-K (Dec 30, 2025). Includes 31 8-K, 6 10-Q, 4 DEF 14A.
View Beyond Air, Inc. on SEC EDGAR
Overview
Beyond Air, Inc. (XAIR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEF 14A filed on Dec 19, 2025: Beyond Air, Inc. (XAIR) is holding its 2026 Annual Meeting of Stockholders on January 30, 2026, at 4:30 p.m. Eastern Time, at its Garden City, New York offices. Key proposals include the election of six directors, the ratification of WithumSmith+Brown, PC as the independent registered public account
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 1 bullish, 4 bearish, 42 neutral, 3 mixed. The dominant filing sentiment for Beyond Air, Inc. is neutral.
Filing Type Overview
Beyond Air, Inc. (XAIR) has filed 31 8-K, 4 DEF 14A, 1 S-1, 6 10-Q, 2 10-K, 2 SC 13G/A, 3 SC 13G, 1 DEFA14A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of XAIR's 44 recent filings, 6 were flagged as high-risk, 25 as medium-risk, and 13 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $1.818M |
| Net Income | -$8.258M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $9.699M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Steven Lisi
- Adam Newman
- Michael McEvoy
Industry Context
Beyond Air, Inc. operates in the medical technology sector, specifically focusing on respiratory conditions. The industry is characterized by significant research and development investment, regulatory hurdles for product approval, and competition from established players and emerging innovators. Trends include the development of novel drug delivery systems and digital health solutions for chronic respiratory diseases.
Top Tags
corporate-governance (7) · 8-k (6) · material-agreement (6) · filing (5) · Biotechnology (4) · Medical Devices (4) · financial-reporting (4) · financial-obligation (4) · 10-Q (4) · financials (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Shares to be added to Equity Incentive Plan | 850,000 | Proposed increase in shares reserved for issuance, potentially leading to dilution |
| Shares of common stock outstanding | 8,009,488 | Total voting shares as of the December 3, 2025 Record Date |
| Number of directors | 6 | Directors to be elected at the Annual Meeting |
| Annual Meeting Date | January 30, 2026 | Date when key proposals will be voted upon by stockholders |
| Shares of Common Stock | 1,600,000 | Number of shares registered for resale by Streeterville Capital, LLC |
| Potential Gross Proceeds | $20,000,000 | Maximum amount Beyond Air may receive from selling common stock to Streeterville under the Purchase Agreement |
| Reverse Stock Split Ratio | 1-for-20 | Ratio of reverse stock split effective July 14, 2025 |
| Share Price | $1.23 | Last reported sale price of XAIR common stock on Nasdaq on November 20, 2025 |
| FDA Approval Date | June 2022 | Date LungFit® PH received premarket approval from the FDA |
| CE Mark Approval Date | November 26, 2024 | Date LungFit® PH received European CE mark approval |
| Ownership in Beyond Cancer | 80% | Beyond Air's ownership stake in its oncology affiliate, Beyond Cancer, Ltd. |
| Ownership in NeuroNOS | 88.2% | Beyond Air's ownership stake in its neurology affiliate, NeuroNOS Limited |
| NO Dosage | 20 ppm | Consistent dosage of NO delivered by LungFit® PH for PPHN, with a range of 0.5 ppm – 80 ppm |
| UNO Concentration | 10,000 ppm | Concentration of ultra-high gaseous nitric oxide delivered by Beyond Cancer's proprietary system for solid tumors |
| Revenue | $1.818M | Increased by 127.8% for the three months ended September 30, 2025, compared to $798K in 2024. |
Forward-Looking Statements
- {"claim":"Beyond Air will continue to operate primarily within the surgical and medical instruments sector.","entity":"Beyond Air, Inc.","targetDate":"2025-12-31","confidence":"high"}
Frequently Asked Questions
What are the latest SEC filings for Beyond Air, Inc. (XAIR)?
Beyond Air, Inc. has 50 recent SEC filings from Jan 2024 to Dec 2025, including 31 8-K, 6 10-Q, 4 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of XAIR filings?
Across 50 filings, the sentiment breakdown is: 1 bullish, 4 bearish, 42 neutral, 3 mixed. The dominant sentiment is neutral.
Where can I find Beyond Air, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Beyond Air, Inc. (XAIR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Beyond Air, Inc.?
Key financial highlights from Beyond Air, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for XAIR?
The investment thesis for XAIR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Beyond Air, Inc.?
Key executives identified across Beyond Air, Inc.'s filings include Steven Lisi, Adam Newman, Michael McEvoy.
What are the main risk factors for Beyond Air, Inc. stock?
Of XAIR's 44 assessed filings, 6 were flagged high-risk, 25 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Beyond Air, Inc.?
Recent forward-looking statements from Beyond Air, Inc. include guidance on {"claim":"Beyond Air will continue to operate primarily within the surgical and medical instruments sector.","entity":"B.